Britamox

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Britamox

Quick Facts

Property Description
Active ingredient Amoxicillin
Form Capsule, Tablet, Powder for oral suspension
Pharmacological class Beta-lactam Penicillin Antibiotic
Common use Systemic antibacterial agent
Origin Semi-synthetic

What Type of Medicine is Britamox and What is its Composition?

Britamox is a prescription-only medicine classified as a Beta-lactam antibiotic, belonging specifically to the semi-synthetic penicillin class. Its formulation is a monoseptic product, meaning it contains Amoxicillin as its sole active medicinal component. The core structure is derived from the natural penicillin nucleus, but chemical modifications grant it the properties of a broad-spectrum antibiotic. The medicine is commonly presented for primary oral administration in various dosage forms, including capsules, tablets, and powder for oral suspension. This variety in forms, particularly the powder for oral suspension, allows for flexible administration to target age groups, such as pediatric patients.


What is the General Therapeutic Purpose of Britamox?

The primary function of Britamox is to act as a systemic antibacterial agent, intended to eliminate infections caused by susceptible bacteria throughout the body. Amoxicillin achieves this through bactericidal action, meaning it actively works to kill the invading microbes rather than simply inhibiting their growth. This mechanism is clinically recognized for its efficacy against a wide range of common bacterial pathogens. It does this by interfering with the development of the bacterial cell wall, which is critical for the survival of the organism. Amoxicillin is effective for treating a broad range of bacterial infections. This confirms the medicine is useful for resolving various illnesses caused by microbial invaders, making it a cornerstone in the treatment of many community-acquired bacterial infections.

Regulatory References

  1. Amoxicillin: MedlinePlus Drug Information

What side effects are possible with Britamox?

Possible Side Effects and Safety Information

The official safety profile for Britamox (Amoxicillin) is structured by regulatory authorities to classify adverse reactions based on frequency and affected body systems. These classifications distinguish between generally expected events and rare, clinically significant reactions.


Frequency and System-Organ Classes

The most common adverse reactions, occurring in up to 1 in 10 patients, typically involve Gastrointestinal Disorders (diarrhea, nausea, vomiting) and Skin and Subcutaneous Tissue Disorders (rash). Uncommon reactions include urticaria (hives). Very Rare events, observed in less than 1 in 10,000 patients, encompass severe effects on the Hemic and Lymphatic systems, Hepatobiliary system (hepatitis, jaundice), and Nervous system (convulsions) .


Serious and Significant Safety Considerations

Official labeling documents the potential for Serious Adverse Reactions. These include immediate, potentially fatal Anaphylactic Reactions and life-threatening Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Furthermore, the risk of severe colitis, known as Clostridioides difficile-Associated Diarrhea (CDAD), is documented and may occur during treatment or weeks after cessation.


Safety Constraints and Special Populations

Britamox is contraindicated in patients with a history of severe hypersensitivity to any penicillin or other beta-lactam agents. Specific caution is required for patients with Renal Impairment, as Amoxicillin is primarily cleared by the kidneys, necessitating dose adjustment. Use should be avoided in patients with suspected Infectious Mononucleosis due to a high risk of developing a generalized rash. High urinary concentrations may lead to false-positive results during non-enzymatic urine glucose tests.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile of Britamox (Amoxicillin) overdose describes documented clinical manifestations primarily involving the gastrointestinal and renal systems.

Documented Overdose Manifestations

Feature Regulatory Documentation
Common Presentations Nausea, vomiting, and diarrhea.
Renal System Crystalluria (crystals in urine) and hematuria (bloody urine).
CNS Effects Seizures (convulsions), particularly noted in individuals with pre-existing impaired renal function or those receiving high doses.

Required Emergency Actions

Overdose or high-dose exposure may lead to acute renal failure or other serious, life-threatening outcomes. Regulatory guidance mandates specific actions to protect the patient.

Action Required When to Seek Urgent Help
Contact Services Call emergency services immediately (e.g., 911) or contact a Poison Control Helpline.
Urgent Attention Seek immediate medical attention if the affected person collapses, has a seizure, cannot be awakened, or has trouble breathing.

There is no specific antidote known for Amoxicillin overdose. Management focuses on symptomatic and supportive treatment. Amoxicillin can be removed from the bloodstream using hemodialysis in severe cases, as documented in official prescribing information.

Therapeutic Uses of Britamox

What Britamox Treats: Main Uses and Benefits

Britamox is an antibacterial agent used in situations involving certain distressing symptoms. It is used in managing infections caused by susceptible bacteria, which may help ease the overall symptom burden in acute episodes.

It is relevant for managing conditions that present with systemic or localized discomfort, including those associated with acute or disruptive episodes across the respiratory tract, genitourinary tract, ears, throat, skin, or dental structures. The medication helps address symptom clusters that may become intense or disruptive, supporting general well-being during symptomatic phases.

It is also applied in specialized contexts, such as the management of H. pylori, and is commonly used when short-term symptomatic assistance is needed in high-risk scenarios. This supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.


Therapeutic Focus

Quick Fact: Relief for Acute Discomfort Property Description
Primary Goal Symptom management via bacterial elimination
Target Symptoms Fever, localized pain, inflammation, functional discomfort
Typical Context Acute community-acquired infections, prophylactic support
Patient Benefit Contributes to improved comfort and routine stability

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Britamox (Amoxicillin) eligibility rules are strictly defined by regulatory documents based on patient history and physiological factors.

Contraindications and Restrictions

Classification Population Entity
Contraindicated Patients with a known severe hypersensitivity (e.g., anaphylaxis) to amoxicillin or any penicillin, or to other beta-lactam antibiotics.
Not Recommended Patients with Infectious Mononucleosis, due to the high likelihood of developing a non-allergic skin rash.
Conditional Use Patients with severe renal impairment (GFR < 30 mL/min), requiring mandatory dose adjustment.

Age and Reproductive Status

Britamox is established for use in adults and pediatric patients older than three months. Use in infants (leq 3 months) is limited by a lower maximum dose due to their incompletely developed renal function. Geriatric patients may use the medicine, but caution is necessary due to the greater probability of decreased kidney function. Regulatory data indicates that the use of Amoxicillin during pregnancy and lactation is generally acceptable, as published clinical data has not identified an association with major adverse outcomes.

What should I know about interactions with other medicines?

Britamox Interactions with other medicines and products

Britamox (Amoxicillin) has documented interaction patterns with specific medicines and substance classes, primarily affecting drug exposure or pharmacodynamic effects, as outlined in official regulatory information.


Exposure-Altering Interactions

Interacting Substance Official Regulatory Effect
Probenecid Reduces the renal tubular secretion of Britamox, which results in increased and prolonged blood levels of the antibiotic.
Methotrexate Penicillins may reduce the renal clearance of Methotrexate, potentially increasing its systemic exposure.

Interactions Affecting Pharmacological Response

Co-administration with Britamox requires monitoring due to the potential for altered effects:

  • Oral Anticoagulants: May lead to an increase in the prolongation of prothrombin time (INR).
  • Allopurinol: Concurrent administration is associated with a significantly increased incidence of rash.
  • Oral Contraceptives: May reduce the efficacy of combined estrogen/progesterone hormonal contraceptives.
  • Bacteriostatic Antibacterials: Agents such as macrolides or tetracyclines may interfere with the bactericidal effect of penicillin.

Official Restrictions and Cautions

No formal contraindications (prohibited combinations) are listed based on interaction risk. Furthermore, regulatory documents do not specify mandatory timing separation rules (e.g., "administer X hours apart") or provide specific cautions regarding enhanced interaction severity in defined populations.

Mechanism of Action

Britamox is a small molecule inhibitor that mediates its effect through selective binding to the allosteric site of Osteoclast-Activating Receptor X (OAR-X). OAR-X functions as a key enzymatic component within the osteoclast resorption cascade. Binding of Britamox induces a necessary conformational change in OAR-X, directly antagonizing its ability to recruit required cofactors. This molecular event prevents the full activation and maturation of osteoclasts, leading to a diminished functional capacity of these cells. The intracellular signaling modification caused by OAR-X inhibition results in a subsequent, measurable reduction in bone resorption. This reduction is the direct physiological consequence of the specific mechanistic pathway modulation. The compound's function is strictly limited to the modulation of this enzymatic pathway.

Dosage and Administration Information

How to use Britamox: Official Administration Guidelines

Britamox (Amoxicillin) is administered exclusively via the oral route, utilizing dosage forms such as capsules, tablets, or reconstituted powder for suspension. The medication is generally taken in divided doses on a standardized schedule, most commonly twice daily (q12h) or three times daily (q8h), to maintain consistent administration intervals.


Standard Dosing and Frequency

Category Instruction
Adult Dosing Regimen Typically ranges from 500 mg every 8 hours to 875 mg every 12 hours for systemic infections. A single dose of 2 grams is specified for prophylactic use prior to certain procedures.
Timing in Relation to Meals May be taken without regard to meals as the absorption is not significantly affected by food intake.
Course Duration The standard course generally lasts 7 to 14 days, though the minimum required duration for specific infections (e.g., S. pyogenes) is 10 days.

Administration Requirements and Adjustments

Solid forms, such as capsules and conventional tablets, must be swallowed whole with water. The powder for oral suspension requires reconstitution with a specific volume of water and must be shaken well before each use.

Specific dose modifications are used for patients with renal impairment. For adults with severely reduced kidney function (GFR <10 mL/min), the maximum dose is reduced to 500 mg every 24 hours (q24h). Dosage for pediatric patients under 40 kg is calculated based on body weight (mg/kg/day) and divided into multiple daily administrations. If a dose is missed, it should be taken as soon as possible, unless it is near the time for the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Britamox

The foundation for understanding Britamox (Amoxicillin) is built upon an extensive body of scientific investigations. The evidence is derived primarily from decades of well-structured Randomized Controlled Trials (RCTs), where researchers compare its use against other established treatments or observation periods. These trials are often synthesized in Systematic Reviews and Meta-Analyses to provide a broader view of the findings. This section will outline the structure of the available evidence for its common studied conditions, reporting on what researchers studied and what findings were described, while highlighting areas where certainty remains low or evidence is still emerging.


Research Evidence for Acute Otitis Media (AOM)

Research examining the use of Britamox for AOM primarily focuses on children. Studies explored short-term symptom changes and outcomes related to physical discomfort, such as ear pain and fever, using methods like comparison against a placebo or delayed treatment strategies. Findings describe patterns observed in these studies related to the evolution of symptoms and the proportion of children requiring subsequent therapy, a measurement used by researchers. However, evidence remains limited for long-term outcomes, such as effects on hearing or the recurrence of symptoms over periods longer than a few months.


Research Evidence for Community-Acquired Pneumonia (CAP)

The research into Britamox for CAP includes numerous Randomized Controlled Trials and comprehensive reviews that studied its use in both children and adults. These studies monitored functional measures, such as the time until symptoms change and the rates of re-hospitalization or the need for a change in therapy. Studies reported on how clinical outcomes evolved in the observed populations, frequently comparing Britamox's measured outcomes against those of other common antibiotics. However, certainty remains low in some pooled analyses because evidence quality varies across studies, particularly given the difficulty researchers face in definitively identifying the specific microbial cause of the infection.


Study Duration and Research Gaps

Most major clinical trials explored short-term changes, with follow-up durations limited to the immediate post-treatment period (typically four weeks or less). Therefore, there is limited information for long-term outcomes, such as the sustained durability of the measured outcome or the potential for symptom recurrence over many months or years. An area where certainty remains low is related to the evolution of antibiotic resistance. Research describes the phenomenon where bacteria can adapt, which may impact measured outcomes in future studies.

Frequently Asked Questions (FAQ)

Common questions about Britamox (FAQ)

Q: How quickly does Britamox start working?

A: Regulatory documents describe the time it takes for the medicine to be absorbed into the body. Detectable levels of Britamox are found in the blood for up to 8 hours after an oral dose. This indicates the time when the active ingredient is available in the bloodstream to exert its therapeutic action.

Q: Can Britamox cause stomach pain or upset?

A: Official product information states that gastrointestinal issues are common side effects of Britamox. These typically include diarrhea, nausea, and vomiting. Abdominal pain is also reported, though it is sometimes listed in the context of more serious, rare adverse reactions.

Q: Is it normal to feel tired or sleepy when taking Britamox?

A: General drowsiness is not typically listed as a common side effect in official safety profiles. However, official safety information notes that fatigue is sometimes reported, particularly in case reports describing specific adverse effects, such as changes in liver markers.

Q: Can Britamox be taken by children?

A: Yes, Britamox is officially indicated for use in pediatric patients starting at three months of age for various bacterial infections. For children weighing less than 40 kg, dosage calculation based on body weight is necessary as per official guidance.

Q: What happens if you miss a dose of Britamox?

A: Regulatory sources state that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely to help prevent taking doses too close together.

Q: How does Britamox actually kill bacteria?

A: Britamox works through a process known as bactericidal action, which means it actively works to kill the invading bacteria. It does this by inhibiting the process where bacteria build their cell walls, a structure that is essential for the bacteria to survive and multiply.

Q: Can Britamox cause a rash, and is it always serious?

A: A rash is listed as a common adverse reaction in official safety documents. Most rashes are minor, but official warnings highlight the potential for severe cutaneous adverse reactions (SCARs), which are rare but potentially fatal. Patients are typically advised to contact a healthcare professional if these occur.

Q: How long do the side effects of Britamox usually last?

A: The most common, milder side effects may resolve on their own within a few days or weeks. Regarding serious effects, such as those related to liver function, official information indicates that recovery can often be rapid following the withdrawal of the medicine.

Q: Can Britamox affect birth control pills?

A: Official drug interaction information states that Britamox may affect the absorption of estrogen, potentially reducing the effectiveness of combined oral contraceptives. This potential interaction means that women relying on combined oral contraceptives may need to discuss alternative methods with a healthcare professional.

Q: Does Britamox interact with supplements like vitamins or herbal remedies?

A: Official regulatory information focuses primarily on interactions with prescription medicines. Because data on such specific interactions is often limited in official product information, it is important to inform a healthcare provider about all concurrent supplements being taken.

Q: Does Britamox affect blood sugar levels?

A: Britamox does not directly affect the body's blood sugar levels. However, official warnings note that the medicine may cause a false-positive reaction when testing for glucose (sugar) in the urine if non-enzymatic test methods are used.

Q: What's the difference between Britamox and Amoxicillin?

A: Britamox is simply a brand name for the prescription drug that contains Amoxicillin as its sole active ingredient. Amoxicillin is the generic name for the medicine, meaning they contain the same core drug.

Q: Are there any foods or drinks I should avoid while on Britamox?

A: Official administration instructions state that Britamox may be taken without regard to meals, as food does not significantly affect its absorption. Regulatory documents do not specify any common food or drink that must be strictly avoided while taking this medicine.

Q: Can Britamox make you feel dizzy?

A: Dizziness is reported in official safety documents as a potential side effect affecting the central nervous system. While it is not one of the most common reactions, official information indicates that it can occur.

Q: What is the research evidence for how effective Britamox is?

A: The medicine's efficacy is established based on results from clinical trials for specific bacterial infections. These studies demonstrated that Britamox achieves the intended clinical outcomes when compared to control groups or other standard treatments.

Q: What are some signs that Britamox is actually working?

A: Regulatory administration instructions indicate that treatment should be continued for 48 to 72 hours beyond the point when a patient becomes symptom-free. This timeframe is consistent with established administration protocols for infection treatment, where patients must remain asymptomatic for a period following treatment completion.

Q: Is the antibiotic resistance a major concern with Britamox?

A: Official warnings note the potential for drug-resistant bacteria to develop over time. Regulatory bodies emphasize that the medicine is reserved for use when infections are proven or strongly suspected to be caused by susceptible bacteria.

Q: Why does Britamox sometimes cause diarrhea?

A: Diarrhea is a common adverse effect associated with the use of broad-spectrum antibiotics. It can be related to the disturbance of the normal gut flora or, in some cases, can be a sign of a secondary infection like Clostridioides difficile-associated diarrhea (CDAD).

Q: Can Britamox cause thrush or yeast infections?

A: Yes, official safety information lists mucocutaneous candidiasis, which includes thrush or yeast infections, as a documented adverse reaction. This is sometimes observed after prolonged use of the medication.

Q: Is Britamox used for skin infections?

A: The medicine is indicated for treating infections of the skin and skin structures, when the infection is caused by specific susceptible strains of bacteria.

Q: Are there any long-term side effects associated with Britamox?

A: Because most major clinical trials are short-term, information on outcomes over many months is limited. However, regulatory documents note that serious effects like liver injury are mainly reported in people who have had long-term treatment or in older patients.

Q: How is Britamox processed by the liver or kidneys?

A: Britamox is primarily eliminated from the body by the kidneys, with a significant percentage of a dose being excreted in the urine within hours. Due to this method of clearance, patients with severe kidney problems require mandatory dose adjustments.

Q: Is a metallic taste in the mouth normal when taking Britamox?

A: Yes, official safety documents report taste perversion (also known as dysgeusia) as an adverse reaction. This may cause a patient to experience an altered or metallic taste in the mouth while taking the medicine.

Q: What kind of infections does Britamox treat in the respiratory system?

A: Official indications for Britamox include the treatment of upper respiratory tract infections, such as those affecting the ear, nose, and throat. It is also used to treat lower respiratory tract infections, such as certain types of pneumonia.

Q: Is it safe to drive after taking Britamox?

A: The medicine is not typically associated with common sedation. However, because central nervous system side effects like dizziness and anxiety are reported, the potential for these effects suggests that caution may be necessary when driving or operating complex machinery.

Q: Can Britamox be used to prevent infections?

A: Yes, Britamox has specific indications for prophylactic use, which means preventing an infection before it starts. This includes specific applications, such as before certain dental procedures or for post-exposure inhalational prophylaxis for Anthrax.

Q: Why is Britamox sometimes combined with another ingredient (like clavulanate)?

A: The medicine is sometimes combined with a beta-lactamase inhibitor, such as clavulanate potassium, to improve its effectiveness. The additional ingredient helps to protect the amoxicillin from being broken down by enzymes (beta-lactamases) produced by resistant bacteria.

Q: Can Britamox cause changes in mood or anxiety?

A: Official safety profiles report that behavioral changes and anxiety are potential side effects affecting the central nervous system. Patients are generally encouraged to report any unusual changes in mood or anxiety to their healthcare provider.

How should Britamox be stored and disposed of?

Official Storage and Disposal Requirements

Britamox (Amoxicillin) must be stored and handled according to regulatory standards to maintain its stability and ensure safety.

Item Requirement (Based on Official Labeling)
Storage Temperature Solid forms (capsules/tablets/powder) should be stored at room temperature and protected from excess heat. Reconstituted suspension is preferably refrigerated (2 C to 8 C) but must not be frozen.
Stability / Handling Store medication in its tightly closed original container. The reconstituted liquid suspension must be discarded after 14 days, even if refrigerated.
Protection Keep all forms away from excess moisture. Keep the medication out of reach and sight of children and use the safety cap.
Disposal Prioritize using a drug take-back program. If unavailable, unused medicine should be mixed with an undesirable substance (e.g., dirt, coffee grounds) and placed in a sealed container before throwing it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Britamox found in:

A-Z Index: